Frequency of Bacteremia due to Carbapenemase-producing Enterobacteriaceae in Pediatric Hematology-Oncology Can Be Reduced by Measures of Hospital Infection Control

Abstract

Objectives: The spread of carbapenemase-producing Enterobacteriaceae (CPE) is an emerging problem in children undergoing cancer-directed chemotherapy. A previous Italian survey reported a threefold increase in CPE colonization rate and a fourfold increase of CPE bloodstream infections in a 2 year-observation time interval. Methods: To assess the efficacy of the measures put in place to control this emergency, a second survey was performed in the years 2016-2017 and the results were compared. Results: The overall rate of colonization was comparable between the two study periods: 0.50% (2016-2017) vs. 0.48% (2012-2013). MDR/CPE bacteremia was now reported in 13 children from six centers. The rate of MDR/CPE bacteremia was 0.12 for 1,000 days of hospitalization (95% CI, 0.07-0.21) and compared favorably with that observed in the previous survey (0.42 for 1,000 days of hospitalization; 95% CI, 0.31-0.57; p<0.0001). The strains responsible for bacteremia were Klebsiella pneumonia in 9/13 children, Escherichia coli in 2/13, Citrobacter spp. and Stenotrophomonas maltophilia in one case each. The antibiotic susceptibility was available for 10 MDR/CPE strains. Conclusion: The number of patients colonized by CPE remained stable over the years, while the number of bloodstream infections decreased, as well as the resulting mortality. We conclude that children undergoing chemotherapy are at risk for CPE colonization/infection but the awareness of their colonization status may allow reducing CPE morbidity and mortality. J Microbiol Infect Dis 2021; 11(1):27-31.

Keywords

• Carbapenemase-producing Enterobacteriaceae
• children
• oncology
• hematology
• infection control

References

1. 1. Tassios GL, Daikos LS, Tzouvelekis A, Markogiannakis M, Psichogiou PT. Carbapenemases in Klebsiella pneumoniae and other Enterobacteriaceae: an evolving crisis of global dimensions. Clin Microbiol Rev 2012; 25:682–707.
2. 2. Queenan AM, Bush K. Carbapenemases: the versatile b-lactamases. Clin Microbiol Rev 2007; 20:440–58.
3. 3. Tsioutis C, Eichel VM, Mutters NT. Transmission of Klebsiella pneumoniae carbapenemase (KPC)-producing Klebsiella pneumoniae: the role of infection control. J Antimicrob Chemother. 2021; 76 (Supplement 1):i4-i11.
4. 4. Caselli D, Cesaro S, Fagioli F, et al. Incidence of colonization and bloodstream infection with carbapenem-resistant Enterobacteriaceae in children receiving antineoplastic chemotherapy in Italy. Infect Dis 2016; 48:152-5.
5. 5. Iacchini S, Sabbatucci M, Gagliotti C, et al. Bloodstream infections due to carbapenemase-producing Enterobacteriaceae in Italy: results from nationwide surveillance, 2014 to 2017. Euro Surveill. 2019;24(5):1800159.
6. 6. Magiorakos AP, Burns K, Rodríguez Baño J. et al. Infection prevention and control measures and tools for the prevention of entry of carbapenem-resistant Enterobacteriaceae into healthcare settings: guidance from the European Centre for Disease Prevention and Control. Antimicrob Resist Infect Control 6, 113 (2017).
7. 7. Arendrup MC, Hope W, Howard SJ. EUCAST Definitive Document E.Def 9.2 Method for the Determination of Broth Dilution Minimum Inhibitory Concentrations of Antifungal Agents for Conidia Forming Moulds; EUCAST: Basel, Switzerland, 2014.
8. 8. Clinical Laboratory Standards Institute. Reference Method for Broth Dilution Antifungal Susceptibility Testing of Filamentous Fungi; Approved Standard, 2nd ed.; CLSI document M38-A2; Clinical and Laboratory Standards Institute: Wayne, PA, USA, 2008.

9. 9. Martelius T, Jalava J, Kärki T, et al. Nosocomial bloodstream infections caused by Escherichia coli and Klebsiella pneumoniae resistant to third-generation cephalosporins, Finland, 1999-2013: Trends, patient characteristics and mortality. Infect Dis 2016; 48:229-34.
10. 10. Marín M, Gudiol C, Garcia-Vidal C, Ardanuy C, Carratalà J. Bloodstream infections in patients with solid tumors: epidemiology, antibiotic therapy, and outcomes in 528 episodes in a single cancer center. Medicine (Baltimore). 2014;93(3):143-9.
11. 11. Avendano E, Raman G, Chan J, McCann E. Burden of carbapenem non-susceptible infections in high-risk patients: systematic literature review and meta-analysis. Antimicrob Resist Infect Control 2020; 9: 193.
12. 12. Viale P, Tumietto F, Giannella M, et al. Impact of a hospital-wide multifaceted programme for reducing carbapenem-resistant Enterobacteriaceae infections in a large teaching hospital in northern Italy. Clin Microbiol Infect 2015; 21(3):242-7.
13. 13. Spyridopoulou K, Psichogiou M, Sypsa V, et al. Containing Carbapenemase-producing Klebsiella pneumoniae in an endemic setting. Antimicrob Resist Infect Control 2020; 9(1):102.